A Double-blind, Placebo Controlled, Cross-over Renal Mechanistic Trial to Assess the Effect of Adding Empagliflozin Versus Placebo on Renal Hyperfiltration in Patients With Type 1 Diabetes on a Background of the Angiotensin Converting Enzyme Inhibitor (ACEi) Ramipril: BETWEEN Study
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Empagliflozin (Primary) ; Ramipril
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms BETWEEN
- Sponsors Boehringer Ingelheim
- 11 Apr 2017 Status changed from active, no longer recruiting to recruiting.
- 24 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 18 Nov 2016 Planned End Date changed from 1 Sep 2017 to 1 Jan 2018.